Tech Guru - always enjoy your posts. One further
Post# of 148158
Unblinding the data does not equate with stopping the trial. The trial will continue.
So, to me, the decision comes more about the risks of unblinding:
1. p-value penalty. Not concerned with this, per my prior post.
2. "the hanging sword of misuse and the trial being rendered invalid" - I'm not sure what this is about, or how we mitigate it.
Benefits (offsetting the risks): publicity; faster future trial enrollment; getting on the radar of foreign countries sooner; learning sooner if something might be fouled up that would cause us to take a different tack (this could be super important, saving us time and money); potential for higher stock price now, helping us raise capital.